The company has entered into a collaboration to develop a care monitoring platform.

In a preview of her HIMSS22 session, Abbott's Jennifer Jones-McMeans explains how clinical studies can be structured to ensure a diverse population of participants.

The company's REMI product is currently FDA cleared for in-hospital use, but Epitel plans to expand into ambulatory and in-home care.

Emme will bring its telemedicine service and smart birth control pill case into the deal. 

The company's total raise is now $75 million.